Noticias

Noticias

  • Título: Transcatheter Technologies to Expand Product Pipeline with Tumbao EndoVascular Aortic Repair (EVAR) System
  • Fecha: 20-01-2015

  • Platform technology allows for unprecedented precision-controlled expansion and anchoring of self-expanding Nitinol stents

    REGENSBURG, Germany, Jan. 20, 2015 — Transcatheter Technologies GmbH, an emerging medical device company that has developed a full range of transcatheter valve implantation systems for catheter-based heart valve therapy, announced today that it is further expanding its product platform to include an EndoVascular Aortic Repair (EVAR) device: Tumbao. (Click here for animation.)

    A thoracic or abdominal aortic aneurysm is a dilatation of the aortic vessel that occurs in 2-8% of patients older than 50 years. The dilatation presents none or few symptoms until rupture. In patients suffering a ruptured aortic aneurysm, the mortality is up to 80 percent. The most common methods of aortic repair are traditional open surgery and EVAR. In the surgical procedure, the wall of the aneurysm is replaced with a synthetic graft. In the EVAR procedure, a stent graft is inserted percutaneously through the femoral artery into the aneurysm. Unlike surgical aortic repair, recovery after EVAR is typically very fast.

    The unique feature of the Transcatheter Technologies platform allows for unprecedented precision-controlled expansion and anchoring of self-expanding Nitinol stents for the treatment of complex aortic aneurysm. With this proprietary system a stent can be repositioned—or even retrieved—if needed.

    “We are expanding our platform technology to comprise not only Trinity TAVI for the treatment of aortic stenosis and Tresillo TMVI for the treatment of mitral valve insufficiency, but also a unique system, Tumbao, for endovascular aortic repair. Tumbao is designed to make aortic stenting more precise and safer,” said Wolfgang Goetz, M.D., Ph.D., CEO. “This coated endovascular stent allows for extraordinarily precise positioning and anchoring, thus making the treatment of more complex aortic disorders possible.

    “Additionally, a short version of Tumbao can seal endoleaks between an existing aortic stent and the native aortic wall (endovascular aortic sealing),” said Dr. Goetz. “An endoleak is a persisting leak into the aneurysm sac, a common complication of EVAR.”

    About Transcatheter Technologies GmbH

    Transcatheter Technologies GmbH is a privately held medical device company headquartered in Regensburg, Germany. Transcatheter Technologies GmbH is developing a range of products for the treatment of structural heart diseases and aortic disorders.

    For more Information visit: www.transcatheter-technologies.com CAUTION: The Trinity, Tresillo, and Tumbao systems are not approved for sale or investigational use in the U.S.

    #####



  • Fuente: endovascular.es